Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleosi...

Full description

Saved in:

Bibliographic Details
Published in:	AIDS Research and Treatment Vol. 2015; no. 2015; pp. 129 - 139
Main Authors:	Orrell, Catherine, Felizarta, Franco, Nell, André, Kakuda, Thomas N., Lavreys, Ludo, Nijs, Steven, Tambuyzer, Lotke, Van Solingen-Ristea, Rodica, Tomaka, Frank L.
Format:	Journal Article
Language:	English
Published:	Cairo, Egypt Hindawi Limiteds 01-01-2015 Hindawi Publishing Corporation John Wiley & Sons, Inc Hindawi Limited
Subjects:	Antiretroviral drugs Atazanavir Clinical Study Dosage and administration Drug dosages Drug resistance Etravirine Health aspects Highly active antiretroviral therapy HIV HIV (Viruses) Human immunodeficiency virus Patients Pharmacokinetics Studies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n=22 each group) over 48 weeks. Results. At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir Cmin⁡ by 18% and 9%, respectively, with no change in AUC24 h or Cmax⁡ versus atazanavir/ritonavir 300/100 mg qd alone (Day −1). Etravirine AUC12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions. Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment.
AbstractList	Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n=22 each group) over 48 weeks. Results. At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir Cmin⁡ by 18% and 9%, respectively, with no change in AUC24 h or Cmax⁡ versus atazanavir/ritonavir 300/100 mg qd alone (Day −1). Etravirine AUC12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions. Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment. Objectives . TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods . After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd ( n = 22 each group) over 48 weeks. Results . At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir C min⁡ by 18% and 9%, respectively, with no change in AUC 24 h or C max⁡ versus atazanavir/ritonavir 300/100 mg qd alone (Day −1). Etravirine AUC 12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions . Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment. Objectives . TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods . After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd ( n = 22 each group) over 48 weeks. Results . At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir C min ⁡ by 18% and 9%, respectively, with no change in AUC 24 h or C max ⁡ versus atazanavir/ritonavir 300/100 mg qd alone (Day −1). Etravirine AUC 12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions . Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment. Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n = 22 each group) over 48 weeks. Results. At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir [C.sub.min] by 18% and 9%, respectively, with no change in [AUC.sub.24h] or [C.sub.max] versus atazanavir/ritonavir 300/100 mg qd alone (Day -1). Etravirine [AUC.sub.12h] was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 273%, resp.). Conclusions. Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment. Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n = 22 each group) over 48 weeks. Results. At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir C min⁡ by 18% and 9%, respectively, with no change in AUC24 h or C max⁡ versus atazanavir/ritonavir 300/100 mg qd alone (Day -1). Etravirine AUC12 h was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions. Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment. [ProQuest: [...] denotes non US-ASCII text; see PDF] Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two nucleoside reverse transcriptase inhibitors (NRTIs) and atazanavir/ritonavir 300/100 mg, 44 patients received etravirine 200 mg bid with one NRTI, plus atazanavir/ritonavir 300/100 mg or 400/100 mg qd (n=22 each group) over 48 weeks. Results. At steady-state etravirine with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd decreased atazanavir [subscript]Cmin[...][/subscript] by 18% and 9%, respectively, with no change in [subscript]AUC24 h[/subscript] or [subscript]Cmax[...][/subscript] versus atazanavir/ritonavir 300/100 mg qd alone (Day -1). Etravirine [subscript]AUC12 h[/subscript] was 24% higher and 16% lower with atazanavir/ritonavir 300/100 or 400/100 mg qd, respectively, versus historical controls. At Week 48, no significant differences were seen between the atazanavir/ritonavir groups in discontinuations due to adverse events (9.1% each group) and other safety parameters, the proportion of patients with viral load <50 copies/mL (intent-to-treat population, noncompleter = failure) (50.0%, atazanavir/ritonavir 300/100 mg qd versus 45.5%, 400/100 mg qd), and virologic failures (31.8% versus 27.3%, resp.). Conclusions. Etravirine 200 mg bid can be combined with atazanavir/ritonavir 300/100 mg qd and an NRTI in HIV-1-infected, treatment-experienced patients without dose adjustment.
Audience	Academic
Author	André Nell Steven Nijs Frank L. Tomaka Rodica Van Solingen-Ristea Franco Felizarta Ludo Lavreys Thomas N. Kakuda Lotke Tambuyzer Catherine Orrell
AuthorAffiliation	3 Parexel International, University of the Free State, Campus Avenue South, Bloemfontein, Free State 9301, South Africa 5 Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium 4 Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA 1 Desmond Tutu HIV Foundation, UCT Medical School, P.O. Box 13801, Mowbray, Cape Town 7705, South Africa 2 Private Practice, 3535 San Dimas Street, Suite 24, Bakersfield, CA 93301, USA
AuthorAffiliation_xml	– name: 2 Private Practice, 3535 San Dimas Street, Suite 24, Bakersfield, CA 93301, USA – name: 1 Desmond Tutu HIV Foundation, UCT Medical School, P.O. Box 13801, Mowbray, Cape Town 7705, South Africa – name: 3 Parexel International, University of the Free State, Campus Avenue South, Bloemfontein, Free State 9301, South Africa – name: 4 Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA – name: 5 Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
Author_xml	– sequence: 1 givenname: Catherine surname: Orrell fullname: Orrell, Catherine organization: Desmond Tutu HIV Foundation, UCT Medical School, P.O. Box 13801, Mowbray, Cape Town 7705 South Africa uct.ac.za – sequence: 2 givenname: Franco surname: Felizarta fullname: Felizarta, Franco organization: Private Practice, 3535 San Dimas Street, Suite 24, Bakersfield, CA 93301 USA – sequence: 3 givenname: André surname: Nell fullname: Nell, André organization: Parexel International, University of the Free State, Campus Avenue South, Bloemfontein, Free State 9301 South Africa – sequence: 4 givenname: Thomas N. surname: Kakuda fullname: Kakuda, Thomas N. organization: Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200 USA janssenrnd.com – sequence: 5 givenname: Ludo surname: Lavreys fullname: Lavreys, Ludo organization: Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse Belgium – sequence: 6 givenname: Steven surname: Nijs fullname: Nijs, Steven organization: Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse Belgium – sequence: 7 givenname: Lotke surname: Tambuyzer fullname: Tambuyzer, Lotke organization: Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse Belgium – sequence: 8 givenname: Rodica surname: Van Solingen-Ristea fullname: Van Solingen-Ristea, Rodica organization: Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200 USA janssenrnd.com – sequence: 9 givenname: Frank L. surname: Tomaka fullname: Tomaka, Frank L. organization: Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200 USA janssenrnd.com
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25664185$$D View this record in MEDLINE/PubMed
BookMark	eNqNk01v1DAQhiNUREvpiTuKhIQQsK0_k_iCtKoKXamCqipcrYnjNC5Ze7G9LfC3-IPMdkvpIg4khxmPn3njmYwfF1s-eFsUTynZp1TKA0aoPFC8qVjzoNhhRJEJZVJt3fmCbBd7KV0SfIQUSlSPim0mq0rQRu4UP08HiHMw4YvzNjuTytCXRznClYsYKQ_DvEXbldcuD-U0ww_wq72DM5fDjVeC70ooPyzNaENynS3P7JWNyZbnEXwy0S0y4GrmB9diUiydL6c-u2hzDCgAI5IW8tz6PDn6trDRWW9s96Y8nn2e0MnM99ZkPMIpZNzJ6UnxsIcx2b1bu1t8end0fng8Ofn4fnY4PZlATUiegBHQ07aX1IIAboVopGh7Lo2hAioFtKukUkwaqOpG9ByIsIKD6tvaqIbw3WK21u0CXOpFdHOI33UAp28CIV5oiNiz0eqGkLoTKNu12GOQoKSVXcWFUr3iIFDr7VprsWzntjNYBxa-Ibq5492gL8KVFpyyiikUeHkrEMPXpU1Zz10ydhzB27BMmlaSU06lqhB9_hd6GZbRY6s0rYligtc31d1SF4AFON8H_K5ZieqpqBirKecrrf1_UPh2du4MzmLvML6R8OJewmBhzEMK4zK74NMm-HoNmhhSira_awYlejXbejXbej3bSD-737879vckI_BqDQzOd3Dt_k_NImJ7uAdLrvB8u8XJGgC8Btn9aeDpSoYyRgmheu2vTE3wHxHC6s0FZUpTrvgvc0Uhmg
CitedBy_id	crossref_primary_10_1007_s40262_016_0454_8 crossref_primary_10_2174_1389200224666230418093139
Cites_doi	10.1097/01.aids.0000166091.39317.99 10.1128/AAC.48.6.2091-2096.2004 10.1097/QAI.0b013e3181cbd21e 10.3851/imp1648 10.1310/3hl3-hhbd-wklr-xell 10.2165/00126839-200708040-00004 10.1016/s0140-6736(07)61048-4 10.1185/030079905x65439 10.1097/qad.0b013e3283316a5e 10.1001/jama.2014.8722 10.1002/phar.1205 10.3851/IMP1662 10.1111/hiv.12119 10.1177/135965350801300505 10.1038/clpt.2010.181 10.1128/aac.01822-12 10.1111/j.1468-1293.2008.00668.x 10.1097/qai.0b013e318164226a 10.1177/135965350901400114 10.1097/qad.0b013e32833677ac 10.1177/135965350601100407 10.1089/088922204322996509 10.1007/s10928-006-9006-4 10.1093/jac/dkp102 10.1177/1545109709355828 10.1093/jac/dkm298 10.1177/135965350701200511 10.1097/qai.0b013e31815ace6a 10.1016/s0140-6736(07)61047-2 10.1093/jac/dki235
ContentType	Journal Article
Copyright	Copyright © 2015 Catherine Orrell et al. COPYRIGHT 2015 John Wiley & Sons, Inc. Copyright © 2015 Catherine Orrell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2015 Catherine Orrell et al. 2015
Copyright_xml	– notice: Copyright © 2015 Catherine Orrell et al. – notice: COPYRIGHT 2015 John Wiley & Sons, Inc. – notice: Copyright © 2015 Catherine Orrell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright © 2015 Catherine Orrell et al. 2015
DBID	188 ADJCN AHFXO RHU RHW RHX NPM AAYXX CITATION 3V. 7X7 7XB 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M2O MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.1155/2015/938628
DatabaseName	Airiti Library الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete Hindawi Publishing Complete Hindawi Publishing Subscription Journals Open Access Journals (Hindawi Publishing) PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Research Library Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef PubMed Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2090-1259
Editor	Mangano, Andrea
Editor_xml	– sequence: 1 givenname: Andrea surname: Mangano fullname: Mangano, Andrea
EndPage	139
ExternalDocumentID	oai_doaj_org_article_8007d414adb549a5a95e5d63499f93a4 3796356041 A462271336 10_1155_2015_938628 25664185 1053971 P20151221001_201512_201706290027_201706290027_129_139
Genre	Journal Article
GroupedDBID	188 24P 2UF 3V. 4.4 53G 5VS 6J9 7X7 8AO 8C1 8FI 8FJ 8G5 AAFWJ AAJEY ABDBF ABUWG ADBBV ADRAZ AFKRA AFPKN AHMBA AINHJ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CEFSP CNMHZ DIK DWQXO EBS EJD ESX FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M2O M48 M~E N8Y O5R OK1 PGMZT PIMPY PQQKQ PROAC RHX RNS RPM TUS UKHRP UZ5 ADJCN AHFXO C1A IL9 O5S RHU RHW NPM AAYXX CITATION 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM
ID	FETCH-LOGICAL-a700t-ac4af1bf51ea4a3e44854bf35cc14a69a1d659925ca6784f3a04e43a9fb7c9803
IEDL.DBID	RPM
ISSN	2090-1240
IngestDate	Mon Nov 04 19:59:38 EST 2024 Tue Sep 17 21:27:13 EDT 2024 Fri Aug 16 11:56:37 EDT 2024 Thu Oct 10 19:38:02 EDT 2024 Wed Oct 16 18:06:16 EDT 2024 Tue Oct 15 04:49:39 EDT 2024 Tue Oct 15 02:43:26 EDT 2024 Thu Nov 21 23:37:32 EST 2024 Sat Sep 28 08:07:30 EDT 2024 Sun Jun 02 19:19:08 EDT 2024 Wed Nov 06 06:01:26 EST 2024 Tue Oct 01 22:52:05 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2015
Language	English
License	This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a700t-ac4af1bf51ea4a3e44854bf35cc14a69a1d659925ca6784f3a04e43a9fb7c9803
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Academic Editor: Andrea Mangano
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312629/
PMID	25664185
PQID	1709243780
PQPubID	2037473
PageCount	11
ParticipantIDs	doaj_primary_oai_doaj_org_article_8007d414adb549a5a95e5d63499f93a4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4312629 proquest_miscellaneous_1653131596 proquest_journals_1709243780 gale_infotracmisc_A462271336 gale_infotracacademiconefile_A462271336 gale_healthsolutions_A462271336 crossref_primary_10_1155_2015_938628 pubmed_primary_25664185 hindawi_primary_10_1155_2015_938628 emarefa_primary_1053971 airiti_journals_P20151221001_201512_201706290027_201706290027_129_139
PublicationCentury	2000
PublicationDate	2015-01-01
PublicationDateYYYYMMDD	2015-01-01
PublicationDate_xml	– month: 01 year: 2015 text: 2015-01-01 day: 01
PublicationDecade	2010
PublicationPlace	Cairo, Egypt
PublicationPlace_xml	– name: Cairo, Egypt – name: United States – name: New York
PublicationTitle	AIDS Research and Treatment
PublicationTitleAlternate	AIDS Res Treat
PublicationYear	2015
Publisher	Hindawi Limiteds Hindawi Publishing Corporation John Wiley & Sons, Inc Hindawi Limited
Publisher_xml	– name: Hindawi Limiteds – name: Hindawi Publishing Corporation – name: John Wiley & Sons, Inc – name: Hindawi Limited
References	(2) 2014; 312 (28) 2011; 19 (10) 2005; 56 (11) 2005; 28 (14) 2008; 48 (18) 2007; 370 (24) 2007; 12 (7) 2004; 20 (12) 2006; 11 (34) 2005; 21 Schöller-Gyüre M. Woodfall B. De Marez T. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir Proceedings of the 8th International Congress on Drug Therapy in HIV Infection November 2006 Glasgow, UK Poster P278 (32) 2010; 9 (27) 2009; 14 (31) 2008; 47 EACS European Guidelines for treatment of HIV infected adults in Europe Version 7.1, 2014, http://www.eacsociety.org/Portals/0/140601 EACS%20EN7.02.pdf (6) 2008; 13 (33) 2005; 19 (16) 2013; 57 (17) 2007; 370 (20) 2010; 15 NIAID Division of AIDS table for grading the severity of adult and pediatric adverse events—version 1 2004, http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf (21) 2010; 88 (22) 2004; 48 (29) 2010; 15 (9) 2004; 5 (35) 2010; 54 (36) 2010; 24 (8) 2006; 33 (13) 2007; 60 (3) 2014; 15 (23) 2009; 10 (19) 2009; 23 (25) 2007; 8 (15) 2013; 33 (30) 2009; 63 DHHS guidelines, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services, 2014, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf 19710593 - AIDS. 2009 Nov 13;23(17):2289-300 17713162 - Antivir Ther. 2007;12(5):789-96 23147727 - Antimicrob Agents Chemother. 2013 Jan;57(1):517-23 18771049 - Antivir Ther. 2008;13(5):655-61 15821394 - AIDS. 2005 Apr 29;19(7):685-94 16583266 - J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):399-419 24330011 - HIV Med. 2014 Jan;15 Suppl 1:1-85 16238909 - Curr Med Res Opin. 2005 Oct;21(10):1683-92 18197119 - J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):177-80 17617270 - Lancet. 2007 Jul 7;370(9581):29-38 15996972 - J Antimicrob Chemother. 2005 Aug;56(2):380-7 15155205 - Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6 19320243 - Antivir Ther. 2009;14(1):103-9 19329800 - J Antimicrob Chemother. 2009 Jun;63(6):1233-43 15117450 - AIDS Res Hum Retroviruses. 2004 Mar;20(3):275-8 22156218 - Top Antivir Med. 2011 Nov;19(4):156-64 23456732 - Pharmacotherapy. 2013 Mar;33(3):284-94 17971713 - J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7 20051805 - AIDS. 2010 Feb 20;24(4):503-14 21041921 - Antivir Ther. 2010;15(7):1045-52 17704117 - J Antimicrob Chemother. 2007 Oct;60(4):897-900 17617271 - Lancet. 2007 Jul 7;370(9581):39-48 25038359 - JAMA. 2014 Jul 23-30;312(4):410-25 20134330 - J Acquir Immune Defic Syndr. 2010 Jun;54(2):143-51 16035256 - New Microbiol. 2005 Apr;28(2):119-25 20881958 - Clin Pharmacol Ther. 2010 Nov;88(5):695-703 17596110 - Drugs R D. 2007;8(4):241-8 19207601 - HIV Med. 2009 Mar;10(3):173-81 20071596 - J Int Assoc Physicians AIDS Care (Chic). 2010 Jan-Feb;9(1):34-42 15472794 - HIV Clin Trials. 2004 Jul-Aug;5(4):201-5 21041912 - Antivir Ther. 2010;15(7):975-83 16856615 - Antivir Ther. 2006;11(4):421-9 22 23 25 29 30 31 10 32 33 34 13 35 14 36 15 16 17 18 19 3 7 8 9 20 21
References_xml	– volume: 23 start-page: 2289 issue: 17 year: 2009 end-page: 2300 ident: 19 article-title: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials publication-title: – volume: 56 start-page: 380 issue: 2 year: 2005 end-page: 387 ident: 10 article-title: Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy publication-title: – volume: 9 start-page: 34 issue: 1 year: 2010 end-page: 42 ident: 32 article-title: 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients publication-title: – volume: 10 start-page: 173 issue: 3 year: 2009 end-page: 181 ident: 23 article-title: Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers publication-title: – volume: 24 start-page: 503 issue: 4 year: 2010 end-page: 514 ident: 36 article-title: Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies publication-title: – volume: 12 start-page: 789 issue: 5 year: 2007 end-page: 796 ident: 24 article-title: Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers publication-title: – volume: 57 start-page: 517 issue: 1 year: 2013 end-page: 523 ident: 16 article-title: Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients publication-title: – volume: 19 start-page: 685 issue: 7 year: 2005 end-page: 694 ident: 33 article-title: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures publication-title: – volume: 60 start-page: 897 issue: 4 year: 2007 end-page: 900 ident: 13 article-title: Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice publication-title: – volume: 312 start-page: 410 issue: 4 year: 2014 end-page: 425 ident: 2 article-title: International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel publication-title: – volume: 370 start-page: 29 issue: 9581 year: 2007 end-page: 38 ident: 17 article-title: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial publication-title: – volume: 19 start-page: 156 issue: 4 year: 2011 end-page: 164 ident: 28 article-title: 2011 update of the drug resistance mutations in HIV-1 publication-title: – volume: 88 start-page: 695 issue: 5 year: 2010 end-page: 703 ident: 21 article-title: Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients publication-title: – volume: 14 start-page: 103 issue: 1 year: 2009 end-page: 109 ident: 27 article-title: Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors publication-title: – volume: 8 start-page: 241 issue: 4 year: 2007 end-page: 248 ident: 25 article-title: Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers publication-title: – volume: 33 start-page: 284 issue: 3 year: 2013 end-page: 294 ident: 15 article-title: Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve publication-title: – volume: 21 start-page: 1683 issue: 10 year: 2005 end-page: 1692 ident: 34 article-title: Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial publication-title: – volume: 48 start-page: 2091 issue: 6 year: 2004 end-page: 2096 ident: 22 article-title: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients publication-title: – volume: 28 start-page: 119 issue: 2 year: 2005 end-page: 125 ident: 11 article-title: Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir publication-title: – volume: 54 start-page: 143 issue: 2 year: 2010 end-page: 151 ident: 35 article-title: Similar safety and efficacy of once-and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks publication-title: – volume: 370 start-page: 39 issue: 9581 year: 2007 end-page: 48 ident: 18 article-title: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial publication-title: – volume: 13 start-page: 655 issue: 5 year: 2008 end-page: 661 ident: 6 article-title: Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients publication-title: – volume: 15 start-page: 1 year: 2014 end-page: 85 ident: 3 article-title: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) publication-title: – volume: 15 start-page: 1045 issue: 7 year: 2010 end-page: 1052 ident: 20 article-title: Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials publication-title: – volume: 15 start-page: 975 issue: 7 year: 2010 end-page: 983 ident: 29 article-title: Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? publication-title: – volume: 63 start-page: 1233 issue: 6 year: 2009 end-page: 1243 ident: 30 article-title: Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers publication-title: – volume: 11 start-page: 421 issue: 4 year: 2006 end-page: 429 ident: 12 article-title: Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study) publication-title: – volume: 47 start-page: 161 issue: 2 year: 2008 end-page: 167 ident: 31 article-title: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients publication-title: – volume: 5 start-page: 201 issue: 4 year: 2004 end-page: 205 ident: 9 article-title: Predictors of virological response to atazanavir in protease inhibitor-experienced patients publication-title: – volume: 20 start-page: 275 issue: 3 year: 2004 end-page: 278 ident: 7 article-title: Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient publication-title: – volume: 33 start-page: 399 issue: 4 year: 2006 end-page: 419 ident: 8 article-title: Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence publication-title: – volume: 48 start-page: 177 issue: 2 year: 2008 end-page: 180 ident: 14 article-title: The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients publication-title: – ident: 33 doi: 10.1097/01.aids.0000166091.39317.99 – ident: 22 doi: 10.1128/AAC.48.6.2091-2096.2004 – ident: 35 doi: 10.1097/QAI.0b013e3181cbd21e – ident: 29 doi: 10.3851/imp1648 – ident: 9 doi: 10.1310/3hl3-hhbd-wklr-xell – ident: 25 doi: 10.2165/00126839-200708040-00004 – ident: 18 doi: 10.1016/s0140-6736(07)61048-4 – ident: 34 doi: 10.1185/030079905x65439 – ident: 19 doi: 10.1097/qad.0b013e3283316a5e – volume: 312 start-page: 410 issue: 4 year: 2014 ident: 2 publication-title: The Journal of the American Medical Association doi: 10.1001/jama.2014.8722 – ident: 15 doi: 10.1002/phar.1205 – ident: 20 doi: 10.3851/IMP1662 – ident: 3 doi: 10.1111/hiv.12119 – volume: 13 start-page: 655 issue: 5 year: 2008 ident: 6 publication-title: Antiviral Therapy doi: 10.1177/135965350801300505 – ident: 21 doi: 10.1038/clpt.2010.181 – ident: 16 doi: 10.1128/aac.01822-12 – ident: 23 doi: 10.1111/j.1468-1293.2008.00668.x – ident: 14 doi: 10.1097/qai.0b013e318164226a – volume: 14 start-page: 103 issue: 1 year: 2009 ident: 27 publication-title: Antiviral Therapy doi: 10.1177/135965350901400114 – ident: 36 doi: 10.1097/qad.0b013e32833677ac – volume: 11 start-page: 421 issue: 4 year: 2006 ident: 12 publication-title: Antiviral Therapy doi: 10.1177/135965350601100407 – ident: 7 doi: 10.1089/088922204322996509 – ident: 8 doi: 10.1007/s10928-006-9006-4 – ident: 30 doi: 10.1093/jac/dkp102 – ident: 32 doi: 10.1177/1545109709355828 – ident: 13 doi: 10.1093/jac/dkm298 – volume: 12 start-page: 789 issue: 5 year: 2007 ident: 24 publication-title: Antiviral Therapy doi: 10.1177/135965350701200511 – volume: 19 start-page: 156 issue: 4 year: 2011 ident: 28 publication-title: Topics in Antiviral Medicine – volume: 28 start-page: 119 issue: 2 year: 2005 ident: 11 publication-title: New Microbiologica – ident: 31 doi: 10.1097/qai.0b013e31815ace6a – ident: 17 doi: 10.1016/s0140-6736(07)61047-2 – ident: 10 doi: 10.1093/jac/dki235
SSID	ssj0000454946
Score	2.03223
Snippet	Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and... Objectives . TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and... [ProQuest: [...] denotes non US-ASCII text; see PDF] Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the...
SourceID	doaj pubmedcentral proquest gale crossref pubmed hindawi emarefa airiti
SourceType	Open Website Open Access Repository Aggregation Database Index Database Publisher
StartPage	129
SubjectTerms	Antiretroviral drugs Atazanavir Clinical Study Dosage and administration Drug dosages Drug resistance Etravirine Health aspects Highly active antiretroviral therapy HIV HIV (Viruses) Human immunodeficiency virus Patients Pharmacokinetics Studies
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgJRAXxHM3UMCIlbhQbRI_Eh8LdNUeWFXLQ9yiie2oEVKKti1I_C3-IDN2ttsgBBdOTeKpHdvjeTgznxk7loUrZUOf_CV4dFBwSYFRdmxLXWd1bVwW0qNn74uzz-XbKcHk7I76opiwCA8cB-4EDZrCyUyCq9GVAYU1eeW0QEu9MQIiEmiq95ypIIMlEocsnTw1FH4g0z45D_UnOvyZOjECjfkSFQ-0BB800EsBvj_k6ALew05c31iSo_y9_ZM5-ntU5Z6aOr3Dbvf2JZ_Eft1l13x3j918139Bv89-Lnqs6i94SxDNfNXwKdb0raU8QI7yAX1l7zht0PLJBn5AR2Un57j0wxWHznHgZwSEvKLDPvm5p9gOz4PeC1IIVSOfd8u2xj9d8Lbjk26DsnVD-xf40kjZh7ePr6CW3Ss-m39CX3Me4sPwFRYR83X9gH08nX54Mxv3BzeMoUjTzRishCarG5V5kCA8uoBK1o1Q1uJEagOZ08qYXFlAXSkbAan0UoBp6sKaMhUP2UG36vwR4xICnhCk1npJaH9GaKe9gxKEaGydsGmcv6pfe-tqQdOb5TmhS1Xxmn6KVOeGvPDhDdo7FVrBCTu-nP7qa8T5qIJ_pFSoo4rskrDXxBo7EgLnDg-QZaueZat_sWzCDnvG2mtKoWGYJewZMVoVc2B3wqeaSJ3ntJ2gE_YyUJD4Qd6w0GdR4GgRkNeAcjSgRLFhB8Uvemb-e39Hl4x-NcA4eoZwLMs0Yc93xVQ_Bex1frVFGo3CXaCtjA0dxnWxawetbE2YSQkrBitmMKrDkq5dBuhzNHdznLlH_2MaHrNb1NO4nzZiB5uLrX_Crq_d9mkQJr8AxrZwQg priority: 102 providerName: Directory of Open Access Journals
Title	Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
URI	https://www.airitilibrary.com/Article/Detail/P20151221001-201512-201706290027-201706290027-129-139 https://search.emarefa.net/detail/BIM-1053971 https://dx.doi.org/10.1155/2015/938628 https://www.ncbi.nlm.nih.gov/pubmed/25664185 https://www.proquest.com/docview/1709243780 https://search.proquest.com/docview/1653131596 https://pubmed.ncbi.nlm.nih.gov/PMC4312629 https://doaj.org/article/8007d414adb549a5a95e5d63499f93a4
Volume	2015
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbYJBAviOsIlGHEJF7omoudxI9ldGofNlXjIt6iE9tZI1g69QISf4s_yDmO2zUI8cBTk9qxY_tcnXM-M3YkMpOLij75C7DooCBLgZK6r_O0jMpSmcilR48_ZOdf8vcjgsmRm1wYF7Svy_q4-XZ13NQzF1t5faUHmzixwfTsBJVenMZqsMf20DbccdGd-BXo8rgEnThUFHkgQp-Xh6oTff1IDlSCdjyd1If6PiX0FlQ_UBOIUEc7ORB_l6kLeA9boX17Ru7yj_pvRumfsZU7yur0PrvnrUw-bEfzgN2yzUN258x_R3_Efk09YvVXvCWgZj6v-Ahb-l5TNiBHKYEeszWctmn5cAU_oaGywQUKAHfFoTEc-DnBIc_pyE9-YSnCw3Kn_ZwsQgXJJ82sLvGhBa8bPmxWKGFXtIuBL401fZB7_wZw2bzl48ln9DgnLkoMX2HaIr8uH7NPp6OPJ-O-P76hD1kYrvqgBVRRWcnIgoDEoiMoRVklUutIQKogMqlUKpYaUGOKKoFQWJGAqspMqzxMnrD9Zt7Yp4wLcKhCEGptBWH-qSQ1qTWQQ5JUugzYqF2_wnPgspjSSkdxTBhTRXtNP1mIhEO-ePcGrZ4CbeGAHW2Wv7hu0T4K5yVJ6dooWsoJ2DsijW0Vguh2f8wXl4Un1AIt8cwIHKkpkSBBIgtYadIEXcxKJSACduAJa6crieZhFLCXRGhFmwm7FUHFUKRxTJsKacDeuBokhJA2NPhcCpwtgvPq1Ox1aqLw0J3i156Y_z3e3obQbyYYZ08RmmUeBuzVtpjap7C9xs7XWCdFEZ-gxYwdHbR8se1nw3sByzoc05nVbgnKAweA7vn_2X8_-ZzdpeG1W2k9tr9arO0Ltrc060O3KXPoRMpvrO1yPg
link.rule.ids	230,315,729,782,786,866,879,887,2106,27933,27934,53800,53802
linkProvider	National Library of Medicine
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbYEJcX7oxAYUZM4oWuudhJ_VhGp1asVTUG2lt0Yjs0gqVTLyDxt_iDnOOkXYMQD3tqXDtxbJ-rc85nxg5EYroip0_-Aiw6KMhSoKRu626cBVmmTODSowefkvF590OfYHLkOhfGBe3rrDgsv18clsXUxVZeXujOOk6sMxkdodIL41B1dthN5Fff33LSnQAW6PS4FJ3QVxR7IPw6Mw-VJ3r7geyoCC15OqsPNX5M-C2ogKAgGKGGfnIw_i5XF7AMG7F9a0oO88_iX2bp39GVW-rq-P41B_qA3avtU96rqh-yG7Z8xG6P6i_wj9nvSY11_Q2LBPHMZznv4xv8KCiPkKN8QV_bGk4bvLy3hF9QUl3nFEWHu-JQGg58TEDKMzoslJ9aig2x3OlNJ8VQtfJhOS0yvGnOi5L3yiXK5iXtf-BgsWUdHt--gmo27_hg-AV91aGLL8NXmFSYsYsn7PNx_-xo0K4PfmhD4vvLNmgBeZDlMrAgILLoQkqR5ZHUOhAQKwhMLJUKpQbUtSKPwBdWRKDyLNGq60dP2W45K-0zxgU4PCLwtbaC0AJVFJvYGuhCFOU681i_Wve05t1FOiEKCcKQ0KnS6pp-Eh9Xgrz4ZgHtpRStaI8drMkmvaxwQlLnX0npnpFWFOex90RSmyYE7u3-mM2_pvXKp0jRiRE4UpMhIYNE5rHSxBE6p7mKQHhsrybIra4kGpaBx_aJQNMqh3YjvNKeiMOQtiNij711LUh8IW1oqLMwcLYICKzRstVoiWJHN6rf1Ezw__G21gxyNcE4e4pwMLu-x15vqun5FPBX2tkK28SoHCK0tbGjvYqfNv2sedZjSYPTGrParEEGc9DpNUM9v_ad--zO4Gx0kp4Mxx9fsLs01GpDrsV2l_OVfcl2Fmb1ygmkP4vJhsw
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zj9MwELbYRax44WYJFNaIlXihm8s5_Fh2W7WCrarlEG_RxHZoBJtWPUDib_EHmXHSboMQD_DUpJ7EsTOnM_OZsWOR6FQU9MlfgMEABUUKZKS6Ko1zP8-l9m159PBdMv6UnvUJJme71ZdN2ld5eVJ9vTypyqnNrZxfKneTJ-ZOzk_R6AVxIN25Ltw9dh1l1gt2AnWrhAUGPrZMJ_Ak5R8Ir6nOQwOKEb8fuTJEb57260OrHxOGCxohKAlKqGWjLJS_rdcFPIet6r4xpaD5e_kn1_T3DMsdkzW4_R-DvcNuNX4q79Ukd9k1U91jB-fNl_j77Oekwbz-gqcE9cxnBe_jU3wrqZ6Qo57BmNtoTgu9vLeCH1BRm3uBKsQecag0Bz4mQOUZbRrKLwzliBhu7afVZmhi-aialjletOBlxXvVCnX0itZBcMBI2aTJd68gm_UrPhx9xJh1ZPPM8BEmNXbs8gH7MOi_Px12mw0gupB43qoLSkDh50XkGxAQGgwlI5EXYaSULyCW4Os4kjKIFKDNFUUInjAiBFnkiZKpFz5k-9WsMo8YF2BxicBTyghCDZRhrGOjIYUwLFTusH797rNGhpfZhLjEDwJCqcrqY_pJPHwbFM23T9BvytCbdtjxhnWyeY0Xktk4K4rsPbKa6xz2mthqS0Ig3_aP2eJz1rz9DH35RAscqc6RmSFCITKRjkMMUgsZgnDYYcOUO11F6GD6DjsiJs3qWtqtEst6Ig4CWpaIHfbSUpAaQ95Q0FRj4GwRIFiLstOiRPWjWs0vGkH4-3g7GyG5mmCcPUl4mKnnsOfbZro_Jf5VZrZGmhiNRIg-N3Z0WMvUtp-N3DosaUlba1bbLShkFkK9EarH_3zlETuYnA2yt6PxmyfsJo20XpfrsP3VYm2esr2lXj-zOukX1IqJTA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+Etravirine+Combined+with+Atazanavir%2FRitonavir+and+a+Nucleoside+Reverse+Transcriptase+Inhibitor+in+Antiretroviral+Treatment-Experienced%2C+HIV-1-Infected+Patients&rft.jtitle=AIDS+research+and+treatment&rft.au=Orrell%2C+Catherine&rft.au=Felizarta%2C+Franco&rft.au=Nell%2C+Andre&rft.au=Kakuda%2C+Thomas+N&rft.date=2015-01-01&rft.pub=Hindawi+Limited&rft.issn=2090-1240&rft.eissn=2090-1259&rft.volume=2015&rft_id=info:doi/10.1155%2F2015%2F938628&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3796356041
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2090-1240&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2090-1240&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2090-1240&client=summon